3600

JC02 Rec'd PCT/PTO 1 3 MAY 2007

Docket No.: NEB-166-PUS

THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS:

Jack, et al..

EXAMINER:

SERIAL NO.

10/089,027

GROUP:

FILED:

March 26, 2002

FOR:

Incorporation of Modified Nucleotides By Archaeon

DNA Polymerases And Related Methods

Assistant Commissioner for Patents Washington, DC 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §1.56, §1.97 and §1.98, Applicants wish to bring the following references, AA-AU, BA-BZ and CA-CF on the attached PTO-1449 Form to the attention of the Examiner.

REMARKS

No representation is made that more pertinent, although presently unknown art does not exist. It is anticipated that the Examiner will conduct a thorough search of the prior art, and will carefully consider each of the said documents cited herein.

Inventors: Jacks, et al. U.S.S.N: 10/089,027 Filed:

Page 2

March 26, 2002

It is respectfully requested that each of the documents shown on the PTO-1449 Form be made of record in this Application.

Early examination and allowance of the present Application is respectfully requested.

Respectfully submitted,

NEW ENGLAND BIOLABS, INC.

Harriet M. Strimpel (Reg. No. 37008) 32 Tozer Road Beverly, MA 01915 (978) 927-5054; Ext: 373

CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT, PTO-1449 FORM and REFERENCES AA-AU, BA-BZ and CA-CF are being deposited with the United States Postal Service as first class mail in an envelope addressed to: ASSISTANT

COMMISSIONER FOR PATENTS, Washington, D.C. 20231 on this day of , 2002.

Melissa A. Jackson

FORM PTO-1449	ATTORNEY NO.	SERIAL NO.
MAY 4 2 2000 H	NEB-166-PUS	10/089,027
INFORMATION DISCLOSURE	APPLICANTS:	
INFORMATION DISCLOSURE	Jack, et al.	
MAG	EILING DATE:	GROUP NO

ILING DATE: GROUP NO

26-Mar-02

	II S D	ATENTS DOCUMENT	<u> </u>				
EXAMINER	0.5. F	ATENTS DOCUMENT DOCUMENT	<u> </u>			SUB-	FILING DATE IF
INITIAL		NUMBER	DATE	NAME	CLASS		APPROPRIATE
IIVITIAL	AA	6,013,431		Soderlund	OBAGO	02.00	ATTOTILATE
	AB	5,500,363		Comb			
	AC	5,614,365		Tabor			
	AD	5,436,149		Barnes		,	
	AE	5,928,906		Koster			-
	AF	5,332,666		Prober			
· · · · · · · · · · · · · · · · · · ·	AG	5,888,819		Goelet			
	АН	5,952,174		Nikiforov			
	AI	6,004,744		Goelet			
	AJ	6,008,025		Komatsubara			
	AK	5,945,312	1999	Goodman			
•	AL	5,352,778	1994	Comb			
· · · · · · · · · · · · · · · · · · ·	AM	5,489,523	1996	Mathur			
	AN	5,834,285	1998	Comb			
	AO	5,756,334	1998	Perler			
	AP	5,827,716	1998	Mamone			
	AQ	5,882,904	1999	Riedl			
	AR	5,723,298	1998	Oommen			
	AS	5,558,991	1996	Trainor			
	AT	5,047,519	1991	Hobbs			
	AU	5,151,507	1992	Hobbs			
	_						
					_		
	 						

FORM PTO-1449		ATTORNEY NO.	SERIAL NO.
4		NEB-166-PUS	10/089,027
INFORMATION DISCLOSURESTATEMENT		APPLICANTS	
/	SIPE YOU	WE Jack	
1	MAY 1 3 2002	FILING DATE	GROUP NO.
	\$	3/26/02	2
ВА	Kongressal., J. Biol. (Chem. 268:1965-1975 (1	993)
BB	New England Biolabs,	Inc. Catalog, 1998/1999,	page 73
BC	Gardner and Jack, Nu	cleic Acids Res. 27:2545	-2553 (1999)
BD	The NEB Transcript, S	September 1992, pages 1	2-13
BE	Brandis, Nucleic Acids	Res. 27:1912-1918 (19	99)
BF	Lee, et al., Nucleic Ac	cids Res. 20:2471-2483 (1992)
BG	Elion, J. Antimicrob. C	Chemother. 12 Suppl. B:9	-17 (1983)
BH	Parker, Biotechniques	19:116-121 (1995)	
			//007\
BI	Altschul, et al. Nucl. A	Acids Res. 25:3389-3402	(1997)
	Takasas ak al EENAG	NA	050 (1000)
BJ	Tatusova, et al. FEMS	Microbiol Lett. 174:247	250 (1999)
BK	Parned et al. Call 50	0:010 000 (1000)	
	Bernad, et al., Cell 59	3.213-220 (1808)	
BL	Derhyshire et al. Sci	ence 240:199-201 (1988)
	Borbysime, et al., 301	21100 240.100-201 (1900	
ВМ	Kornberg DNA Replica	tion, W.H. Freeman and C	ompany, San Francisco
	Section 4-10, pages		1
BN		niques 17:742-753 (1994)
	, , , , , , , , , , , , , , , , , , , ,		
ВО	Delarue, et al., Proteir	n Eng. 3:461-467 (1990)	

•

a)

a) e

•

FORM PT	O-1449		ATTORNEY NO.	SERIAL NO.		
	× .		NEB-166-PUS	10/089,027		
INFORMATION DISCLOSURE STETEMENT		APPLICANTS				
		WE Jack				
		MAY 1 3 2002	FILING DATE	GROUP NO.		
	BP	Concernant al., Bio	techniques 26:870-87	3 (1999)		
****	BQ	Ilsley and Buzby, FA	SEB J. 13:A1441 (199	9)		
	BR	Ito and Braithwaite, I	Nucleic Acids Res. 19	:4045-4057 (1991)		
,,	BS	Perler, et al., Proc. N	Perler, et al., Proc. Natl. Acad. Sci. 89:5566-5581 (1992)			
	вт	Reid, et al., J. Biol.	Reid, et al., J. Biol. Chem 263:3898-3904 (1988)			
	BU	Ross, Nature Biotechnology 16:1347-1351 (1998)				
	BV	Saiki, et al., Science	230:1350-1354 (198	5)		
	BW	Sanger, Proc. Natl.	Acad. Sci. USA 74:54	63-5467 (1977)		
	BX	Southworth, Proc. Na	atl. Acad. Sci. USA 90	3:5281-5285 (1996)		
	BY	Tabor and Richardson, Proc. Natl. Acad. Sci. USA 92:6339-6343 (1995)				
	BZ	Walker, Proc. Natl. Acad. Sci. USA 89:392-396 (1992)				
	CA	Chen, Genome Rese	arch 9:492-498 (1999)		
	CB	Chen and Kwok, Nuc	eleic Acids Res. 15:34	7-353 (1997)		
	œ	Prober, Science 238	:336-341 (1987)			
	Φ	Sarker, Genomics, 1	3:441-443 (1992)			

FORM PTO-	1449	10)	ATTORNEY NO.	SERIAL NO.
	a) av •	4	NEB-166-PUS	10/089,027
		OSUPE STATEMENT	APPLICANTS	
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	0	WE Jack	
		MAY 1 3 2002 岩	FILING DATE	GROUP NO.
		3		6/02
	Œ	Nikiforov Nucleic A	cids Res. 22:4167-4175	5 (1994)
	-	,		
				-
				1477
			-	
		4		
-				
				
				· · · · · · · · · · · · · · · · · · ·
	i:			
-				